Table 2 Overview of the most important inclusion criteria in DAPA-HF and EMPEROR Reduced trials, including patients suffering from heart diseases, independent on diabetes state. Further, the outcomes of the trials are summarized, incl. hazard ratios and confidence intervals (CI).
DAPA-HF | EMPEROR-Reduced | |
|---|---|---|
No. of patients | 4,744 | 3,730 |
Inclusion criteria | ||
≥ 18 years | ≥ 18 years | |
Ejection fraction ≤ 40% and New York Heart Association (NYHA) class II, III, IV symptoms | Left ventricular ejection fraction ≤ 40% and New York Heart Association (NYHA) class II, III, IV symptoms | |
Medication | Required; Angiotensin-converting-enzyme inhibitor, angiotensin-receptor blocker, sacubitril-valsartan plus beta-blocker, mineralocorticoid receptor antagonist | Required incl. Diuretics, inhibitors of the renin-angiotensin system and neprilysin, beta-blockers, mineralocorticoid receptors antagonists |
Outcomes | Reduced incidence of hospitalization due to HF (hazard ratio, 0.70 (95% CI, 0.59 to 0.83) or death from CV (hazard ratio, 0.82 (95% CI, 0.69 to 0.98), observation of renal protective effect | Reduced incidence of hospitalization due to HF (hazard ratio, 0.69 (95% CI, 0.59 to 0.81) or death from CV (hazard ratio, 0.92 (95% CI, 0.75 to 1.12), observation of renal protective effect |